Search

Your search keyword '"Windsor, Sheryl L."' showing total 31 results

Search Constraints

Start Over You searched for: Author "Windsor, Sheryl L." Remove constraint Author: "Windsor, Sheryl L." Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
31 results on '"Windsor, Sheryl L."'

Search Results

1. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

4. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials

5. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

6. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

7. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

8. Association Between Change in Ambulatory Pulmonary Artery Pressures and Natriuretic Peptides in Patients with Heart Failure: Results from the EMBRACE-HF Trial.

9. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

10. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection

11. METABOLIC EFFECTS OF DAPAGLIFLOZIN IN HEART FAILURE ACROSS THE SPECTRUM OF EJECTION FRACTION

12. Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure

13. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.

14. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure

15. Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial

17. Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial

20. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases

21. n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans

29. Safety and Efficacy of Omacor in Severe Hypertriglyceridemia

31. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.

Catalog

Books, media, physical & digital resources